Pretreatment with the protegrin IB-367 affects gram-positive biofilm and enhances the therapeutic efficacy of linezolid in animal models of central venous catheter infection

Journal of Parenteral and Enteral Nutrition

Volumn 31, Issue 6, 2007, Pages 463-468

  Ghiselli, Roberto ^a   Giacometti, Andrea ^a,d   Cirioni, Oscar ^a   Mocchegiani, Federico ^a   Silvestri, Carmela ^a   Orlando, Fiorenza ^b   Kamysz, Wojciech ^c   Licci, Alberto ^a   Nadolski, Piotr ^c   Della Vittoria, Agnese ^a   Łukasiak, Jerzy ^c   Scalise, Giorgio ^a   Saba, Vittorio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d Ospedale Regionale Torrette   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IB 367; LINEZOLID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BIOFILM; CATHETER INFECTION; CENTRAL VENOUS CATHETER; COLONY FORMING UNIT; CONTROLLED STUDY; DEVICE INFECTION; DRUG EFFICACY; ENTEROCOCCUS FAECALIS; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SILICONE PROSTHESIS; STAPHYLOCOCCUS AUREUS; STRAIN IDENTIFICATION; SUPERIOR CAVA VEIN; TISSUE CULTURE;

ACETAMIDES; ANIMALS; ANTI-INFECTIVE AGENTS; BIOFILMS; CATHETERIZATION, CENTRAL VENOUS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCOCCUS FAECALIS; GRAM-POSITIVE BACTERIAL INFECTIONS; MALE; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; PEPTIDES; RANDOM ALLOCATION; RATS; RATS, WISTAR; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

ANIMALIA; BACTERIA (MICROORGANISMS); ENTEROCOCCUS FAECALIS; POSIBACTERIA; RATTUS; RATTUS NORVEGICUS; STAPHYLOCOCCUS AUREUS;

EID: 35748943172     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607107031006463     Document Type: Article

References (31)

1. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318-1322.
2. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167-193.
3. Fux CA, Costerton JW, Stewart PS, Stoodley P. Survival strategies of infectious biofilm. Trends Microbiol. 2005;13:34-40.
4. Atela I, Coll P, Rello J, et al. Serial surveillance cultures of skin and catheter hub specimens from critically ill patients with central venous catheters: molecular epidemiology of infection and implications for clinical management and research. J Clin Microbiol. 1997;35:1784-1790.
5. Wilcox MH, Kite P, Mills K, Sugden S. In situ measurement of linezolid and vancomycin concentrations in intravascular catheter-associated biofilm. J Antimicrob Chemother. 2001;47:171-175.
6. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2:95-108.
7. Amorena B, Gracia E, Monzon M, et al. Antibiotic susceptibility assay for Staphylococcus aureus in biofilms developed in vitro. J Antimicrob Chemother. 1999;44:43-55.
8. Hancock LE, Perego M. The Enterococcus faecalis fsr two-component system controls biofilm development through production of gelatinase. J Bacteriol. 2004;186:5629-5639.
9. Beghetto MG, Victorino J, Teixeira L, de Azevedo MJ. Parenteral nutrition as a risk factor for central venous catheter-related infection. JPEN J Parenter Enteral Nutr. 2005;29:367-373.
10. nd ed. Washington, DC: ASM Press; 2004: 155-212.
11. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 2001;32:1249-1272.
12. Fux CA, Stoodley P, Hall-Stoodley L, Costerton JW. Bacterial biofilms: a diagnostic and therapeutic challenge. Expert Rev Anti Infect Ther. 2003;1:667-683.
13. Raad I. Intravascular-catheter-related infection. Lancet. 1998;351:893-898.
14. Raad I, Hanna H. Intravascular catheters impregnated with antimicrobial agents: a milestone in the prevention of bloodstream infections. Support Care Cancer. 1999;7:386-390.
15. Hancock RE. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis. 2001;1:156-164.
16. Giacometti A, Cirioni O, Greganti G, Quarta M, Scalise G. In vitro activity of membrane-active peptides against Gram-positive and Gram-negative aerobic bacteria. Antimicrob Agents Chemother. 1998;42:3320-3324.
17. Giacometti A, Cirioni O, Barchiesi F, Del Prete MS, Scalise G. Antimicrobial activity of polycationic peptides. Peptides. 1999;20:1265-1273.
18. Cho Y, Turner JS, Dinh NN, Lehrer RI. Activity of protegrins against yeast-phase Candida albicans. Infect Immun. 1998;66:2486-2493.
19. Chen J, Falla TJ, Liu H, et al. Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues. Biopolymers. 2000;55:88-98.
20. Kamysz W, Kochanska B, Kedzia A, et al. Statherin SV2 and its analogue: synthesis and evaluation of antimicrobial activity. Polish J Chem. 2002;76:801-806.
21. Labthavikul P, Petersen PJ, Bradford PA. In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm model. Antimicrob Agents Chemother. 2003;47:3967-3969.
22. Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods. 2000;40:175-179.
23. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard M7-A6. Villanova, PA: Clinical and Laboratory Standards Institute; 2003.
24. Rupp ME, Fey PD, Longo GM. Effect of LY33328 against vancomycin-resistant Enterococcus faecium in a rat model central venous catheter-associated infection model. J Antimicrob Chemother. 2001;47:705-707.
25. Benoit JL, Carandang G, Sitrin M, Arnow P. Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home. Clin Infect Dis. 1997;24:743-744.
26. Faubion WC, Wesley JR, Khalidi N, Silva J. Total parenteral nutrition catheter sepsis: impact of the team approach. JPEN J Parenter Enteral Nutr. 1986;10:642-645.
27. Bozzetti F, Mariani L, Bertinet DB, et al. Central venous catheter complications in 447 patients on home parenteral nutrition: an analysis of over 100,000 catheter days. Clin Nutr. 2002;21:475-485.
28. Giacometti A, Cirioni O, Ghiselli R, et al. Comparative efficacies of quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49:4042-4045.
29. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev. 2003;55:27-55.
30. Morra M, Cassinelli C, Cascardo G, et al. Adsorption of cationic antibacterial on collagen-coated titanium implant devices. Biomed Pharmacother. 2004;58:418-422.
31. Chen H, Zhang Z, Chen Y, Brook MA, Sheardown H. Protein repellant silicone surfaces by covalent immobilization of poly( ethylene oxide). Biomaterials. 2005;26:2391-2399.